ME02476B - KOMBINACIJA N-{[(7S)-3,4-DIMETOKSIBICIKLO[4.2.0)0KTA- 1,3,5-TRIEN-7-IL)METIL}-3-(7,8-DIMETOKSI-1,2,4,5-TETRAHIDRO-3H-3- BENZAZEPIN-3-IL)-N-METIL-3-OKSO-1-PROPANAMINA l PERINDOPRILA - Google Patents

KOMBINACIJA N-{[(7S)-3,4-DIMETOKSIBICIKLO[4.2.0)0KTA- 1,3,5-TRIEN-7-IL)METIL}-3-(7,8-DIMETOKSI-1,2,4,5-TETRAHIDRO-3H-3- BENZAZEPIN-3-IL)-N-METIL-3-OKSO-1-PROPANAMINA l PERINDOPRILA

Info

Publication number
ME02476B
ME02476B MEP-2016-90A MEP9016A ME02476B ME 02476 B ME02476 B ME 02476B ME P9016 A MEP9016 A ME P9016A ME 02476 B ME02476 B ME 02476B
Authority
ME
Montenegro
Prior art keywords
methyl
dimethoxybicyclo
benzazepin
propanamine
trien
Prior art date
Application number
MEP-2016-90A
Other languages
German (de)
English (en)
French (fr)
Inventor
Christian Thuillez
Paulus Mulder
Jean-Paul Vilaine
Marie-Dominique Fratacci
Guy Lerebours-Pigeonniere
Luc Feldmann
Jérôme Roussel
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02476(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ME02476B publication Critical patent/ME02476B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MEP-2016-90A 2010-06-15 2011-06-14 KOMBINACIJA N-{[(7S)-3,4-DIMETOKSIBICIKLO[4.2.0)0KTA- 1,3,5-TRIEN-7-IL)METIL}-3-(7,8-DIMETOKSI-1,2,4,5-TETRAHIDRO-3H-3- BENZAZEPIN-3-IL)-N-METIL-3-OKSO-1-PROPANAMINA l PERINDOPRILA ME02476B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1002525A FR2961105B1 (fr) 2010-06-15 2010-06-15 Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
EP15162899.7A EP2921168B1 (fr) 2010-06-15 2011-06-14 Association de la n-{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-n-methyl-3-oxo-1-propanamine et du perindopril

Publications (1)

Publication Number Publication Date
ME02476B true ME02476B (me) 2017-02-20

Family

ID=42985210

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2016-90A ME02476B (me) 2010-06-15 2011-06-14 KOMBINACIJA N-{[(7S)-3,4-DIMETOKSIBICIKLO[4.2.0)0KTA- 1,3,5-TRIEN-7-IL)METIL}-3-(7,8-DIMETOKSI-1,2,4,5-TETRAHIDRO-3H-3- BENZAZEPIN-3-IL)-N-METIL-3-OKSO-1-PROPANAMINA l PERINDOPRILA
MEP-2015-95A ME02163B (me) 2010-06-15 2011-06-14 Upotreba kombinacije kao inhibitora sinusne struje i inhibitora enzima konverzije angiotenzina za liječenje zatajenja srca s očuvanom sistoličkom funkcijom

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2015-95A ME02163B (me) 2010-06-15 2011-06-14 Upotreba kombinacije kao inhibitora sinusne struje i inhibitora enzima konverzije angiotenzina za liječenje zatajenja srca s očuvanom sistoličkom funkcijom

Country Status (46)

Country Link
US (1) US20110306598A1 (me)
EP (2) EP2404600B1 (me)
JP (1) JP5480202B2 (me)
KR (1) KR101389879B1 (me)
CN (2) CN104906579A (me)
AP (2) AP3691A (me)
AR (1) AR081875A1 (me)
AU (1) AU2011202607B2 (me)
BR (1) BRPI1102830F1 (me)
CA (1) CA2743527C (me)
CL (1) CL2011001420A1 (me)
CO (1) CO6640265A2 (me)
CR (1) CR20120609U (me)
CU (1) CU24161B1 (me)
CY (2) CY1116438T1 (me)
DK (2) DK2404600T3 (me)
EA (1) EA022612B1 (me)
EC (1) ECSP12012337A (me)
ES (2) ES2582157T3 (me)
FR (1) FR2961105B1 (me)
GE (1) GEP20146132B (me)
GT (1) GT201200341A (me)
HK (2) HK1210012A1 (me)
HR (2) HRP20150745T1 (me)
HU (2) HUE027088T2 (me)
IL (1) IL223293A (me)
JO (1) JO3309B1 (me)
MA (1) MA33235B1 (me)
ME (2) ME02476B (me)
MX (1) MX2011006001A (me)
MY (1) MY179034A (me)
NI (1) NI201200182A (me)
NZ (2) NZ593437A (me)
PE (1) PE20120019A1 (me)
PL (2) PL2921168T3 (me)
PT (1) PT2404600E (me)
RS (2) RS54077B1 (me)
SA (2) SA114360089B1 (me)
SG (2) SG10201500502WA (me)
SI (2) SI2404600T1 (me)
TN (1) TN2012000551A1 (me)
TW (1) TWI468164B (me)
UA (1) UA108983C2 (me)
UY (1) UY33423A (me)
WO (1) WO2011157908A1 (me)
ZA (1) ZA201104222B (me)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603666A (zh) * 2012-02-28 2012-07-25 石河子大学 肉桂酰牛磺酰噻唑烷酸类化合物及其应用
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
EP3025705B8 (en) * 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
FR3050380B1 (fr) 2016-04-20 2020-07-10 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
KR20190001340A (ko) * 2017-06-27 2019-01-04 에리슨제약(주) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법
CN107714702A (zh) * 2017-10-31 2018-02-23 泰州中国医药城中医药研究院 一种伊伐布雷定和米力农组合物及其在制药中的应用
CN107550915A (zh) * 2017-10-31 2018-01-09 泰州中国医药城中医药研究院 一种伊伐布雷定和咯利普兰组合物及其在制药中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
US6188743B1 (en) * 1997-10-10 2001-02-13 Analogic Corporation Computed tomography scanner drive system and bearing
FR2807431B1 (fr) * 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
FR2838648B1 (fr) 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
BRPI0516128A (pt) * 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2921365B1 (fr) 2007-09-21 2012-10-12 Servier Lab Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2927538B1 (fr) * 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
RU2364401C1 (ru) * 2008-05-12 2009-08-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции сосудистого ремоделирования у больных хронической сердечной недостаточностью ишемической этиологии
WO2009158005A1 (en) * 2008-06-27 2009-12-30 Concert Pharmaceuticals, Inc. Benzazepinone compounds
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью

Also Published As

Publication number Publication date
IL223293A0 (en) 2013-02-03
CN104906579A (zh) 2015-09-16
ME02163B (me) 2015-10-20
DK2921168T3 (en) 2016-08-01
AU2011202607B2 (en) 2015-02-12
AP2016009002A0 (en) 2016-01-31
BRPI1102830B1 (pt) 2019-10-08
MX2011006001A (es) 2011-12-14
JO3309B1 (ar) 2018-09-16
HRP20150745T1 (hr) 2015-08-14
PL2921168T3 (pl) 2016-10-31
GT201200341A (es) 2014-03-14
EP2404600B1 (fr) 2015-05-27
JP2012001545A (ja) 2012-01-05
HRP20160643T1 (hr) 2016-07-01
EP2404600A1 (fr) 2012-01-11
SI2404600T1 (sl) 2015-10-30
BRPI1102830B8 (pt) 2020-01-07
SG177069A1 (en) 2012-01-30
TW201206445A (en) 2012-02-16
IL223293A (en) 2017-04-30
EP2921168B1 (fr) 2016-04-13
US20110306598A1 (en) 2011-12-15
JP5480202B2 (ja) 2014-04-23
TWI468164B (zh) 2015-01-11
EA201100773A1 (ru) 2011-12-30
AU2011202607A1 (en) 2012-01-12
NZ593437A (en) 2012-08-31
UY33423A (es) 2011-12-30
PL2404600T3 (pl) 2015-10-30
AP3691A (en) 2016-04-30
SA111320527B1 (ar) 2015-03-19
BRPI1102830F1 (pt) 2022-03-29
MY179034A (en) 2020-10-26
ES2545343T3 (es) 2015-09-10
CA2743527A1 (fr) 2011-12-15
WO2011157908A1 (fr) 2011-12-22
UA108983C2 (en) 2015-07-10
FR2961105A1 (fr) 2011-12-16
CU20120166A7 (es) 2013-04-19
PT2404600E (pt) 2015-07-13
EP2921168A1 (fr) 2015-09-23
CA2743527C (fr) 2016-08-02
HUE027088T2 (en) 2016-08-29
KR20110136752A (ko) 2011-12-21
CL2011001420A1 (es) 2012-07-06
AR081875A1 (es) 2012-10-24
HK1210012A1 (en) 2016-04-15
DK2404600T3 (en) 2015-08-31
CU24161B1 (es) 2016-03-31
BRPI1102830A2 (pt) 2013-12-24
MA33235B1 (fr) 2012-05-02
SA114360089B1 (ar) 2016-02-03
CY1117724T1 (el) 2017-05-17
CR20120609U (es) 2013-02-05
GEP20146132B (en) 2014-08-11
CY1116438T1 (el) 2017-02-08
RS54838B1 (sr) 2016-10-31
KR101389879B1 (ko) 2014-04-29
ES2582157T3 (es) 2016-09-09
AP2013006661A0 (en) 2013-01-31
FR2961105B1 (fr) 2013-02-08
EA022612B1 (ru) 2016-02-29
CO6640265A2 (es) 2013-03-22
WO2011157908A8 (fr) 2013-01-17
TN2012000551A1 (fr) 2014-04-01
NI201200182A (es) 2013-05-13
SI2921168T1 (sl) 2016-08-31
CN102284060A (zh) 2011-12-21
ZA201104222B (en) 2012-02-29
HUE027788T2 (en) 2016-10-28
PE20120019A1 (es) 2012-02-11
HK1210011A1 (zh) 2016-04-15
RS54077B1 (en) 2015-10-30
SG10201500502WA (en) 2015-03-30
ECSP12012337A (es) 2012-12-28
NZ600931A (en) 2013-04-26

Similar Documents

Publication Publication Date Title
ME02476B (me) KOMBINACIJA N-{[(7S)-3,4-DIMETOKSIBICIKLO[4.2.0)0KTA- 1,3,5-TRIEN-7-IL)METIL}-3-(7,8-DIMETOKSI-1,2,4,5-TETRAHIDRO-3H-3- BENZAZEPIN-3-IL)-N-METIL-3-OKSO-1-PROPANAMINA l PERINDOPRILA
PL2166004T3 (pl) Nowy sposób rozdzielania enancjomerów (3,4-dimetoksy-bicyklo[4.2.0]okta -1,3,5-trien -7-ylo)nitrylu i ich zastosowanie do syntezy iwabradyny
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
HK1140188A1 (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin- 2-one, and application thereof
MX2012010859A (es) Formas polimorficas st-246 y metodos de preparacion.
EP2365950A4 (en) PRODUCTION OF PHEROMONES AND PERFUMES FROM SUBSTITUTED AND NON-SUBSTITUTED 1-ALKEN-3-YL ALKYLATES
UA103996C2 (en) Ivabradine hydrobromide
GEP20135970B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
PL2687506T3 (pl) Sposób syntezy enzymatycznej (7S)-1-(3,4-dimetoksy bicyklo[4.2.0]okta-1,3,5-trien-7-ylo)-N-metylometanoaminy i zastosowanie do syntezy iwabradyny i jej soli
CL2012003136A1 (es) Procedimiento de sintesis de 3-{3-[{[(7s)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil}(metil)amino]propil}-7,8-dimetoxi-1,3,4,5-tetrahidro-2h-3-benzazepin-2-ona (ivabradina).
PL2626428T3 (pl) Sposób syntezy enzymatycznej kwasu (7S)-3,4-dimetoksybicyklo[4.2.0]okta-1,3,5-trien-7-karboksylowego lub jego estrów i zastosowania do syntezy iwabradyny i jej soli
EP2233465A4 (en) PROCESS FOR THE PREPARATION OF RIVASTIGMIN, THEIR INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING THE INTERMEDIATE PRODUCTS
HRP20150950T1 (en) Method for enzymatic synthesis of (7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid, and use for the synthesis of ivabradine and the salts thereof
IL212749A0 (en) Novel forms of an indazolo [5,4-a] carbazole compound
HU0800399D0 (en) Process for the preparation of 1-(3,4-dimethoxy-phenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine with high purity
PL390310A1 (pl) Sposób wytwarzania (Z)-3,7,11-trimetylododeka-1,6-dien-3,10,11-triolu i (Z)-2,10-dihydroksy-2,6,10-trimetylododeka-6,11-dien-3-onu
PL390802A1 (pl) Nowy cis(-)-2-hydroksy-4,6,6-trimetylo-9-oksabicyklo [4.3.0] nonan-8-on i sposób jego otrzymywania
PL390309A1 (pl) Sposób otrzymywania (Z)-3,7,11-trimetylododeka-1,6-dien-3,10,11-triolu i (Z)-2,10-dihydroksy-2,6,10-trimetylododeka-6,11-dien-3-onu
PL387935A1 (pl) Nowy (Z)-2"-(2"'-hydroksyizopropylo)-dihydrofurano-[2",3":6,7]-3',4'-dihydroksy -4-metoksyauron i sposób jego wytwarzania
AU323753S (en) Mounting bracket
PL390801A1 (pl) Nowy cis 2-hydroksy-4,6-dimetylo-9-oksabicyklo[4.3.0]nonan-8-on i sposób jego otrzymywania